Peking Union Medical College Overview

Trial Radar AI Insights

Peking Union Medical College

Peking Union Medical College leads extensive clinical research in China, spearheading 356 active trials as lead sponsor that advance treatments in oncology, neurology, and infectious diseases, offering patients access to cutting-edge therapies through its affiliated hospitals. Its patient-centric approach emphasizes high-enrollment studies, particularly for cancers and chronic conditions, enhancing trial opportunities for diverse populations.

• Institution Profile: Founded 1917 · Beijing, China · Public · https://english.pumc.edu.cn
• Therapeutic Strengths: Oncology, neurology, infectious diseases
• Partnerships: Collaborates with Tsinghua University; affiliates include Cancer Hospital of Chinese Academy of Medical Sciences and Fu Wai Hospital

Clinical Research Infrastructure

Peking Union Medical College anchors a robust ecosystem of research hospitals and institutes in Beijing, conducting trials at flagship sites like Peking Union Medical College Hospital. Key affiliates, such as Cancer Hospital of Chinese Academy of Medical Sciences for oncology and Fu Wai Hospital for cardiovascular studies, expand site capacity across 518 locations, all in China. Child organizations like the Institute of Basic Medical Sciences and State Key Laboratory of Virus Genetic Engineering support preclinical-to-clinical translation.

Key Specialties and Therapeutic Focus

• Primary focus areas (prioritized by expertise and reputation):
  • Oncology, targeting breast cancer (14 trials), cervical cancer, pancreatic cancer, lung cancer, rectal cancer, and endometrial cancer; employs chemotherapy, immunotherapy (e.g., toripalimab), targeted therapies (e.g., lenvatinib), and neoadjuvant approaches
  • Neurology, addressing dementia (including vascular and Lewy body types) and multimorbidity via observational and interventional studies
  • Infectious diseases, focusing on HPV infection (100,030 enrolled participants); incorporates diagnostics like PET/CT and 68Ga-FAPI imaging
  • Hematology, studying aplastic anemia
• Therapeutic modalities center on drugs (316 interventions), procedures (60), and diagnostic tests (46), with emerging use of biologics, devices, and biomarkers for prognosis and efficacy

Peking Union Medical College Clinical Trials Landscape

Trial StatisticsApply Below Filters

Peking Union Medical College leads 356 active trials—215 recruiting—as sponsor, spanning 518 locations exclusively in China and enrolling 329,956 participants at an average of 927 per trial. Studies predominantly target adults (344 trials) and older adults (319 trials), with 40 pediatric trials; interventional designs (244) outnumber observational (112), emphasizing female participants (70 trials) over male (5) or all (281). High-enrollment conditions include HPV infection and dementia variants, featuring drugs like chemotherapy and toripalimab alongside imaging biomarkers.

Key Clinical Trial Updates

Seven trials updated in October 2025 highlight ongoing momentum in oncology and neurology, with phase distributions favoring phase 2 (86 trials) and unphased studies (102). Primary completion dates approach for several phase 3 efforts in cancer immunotherapy, potentially yielding efficacy data in 2026.

Trial Innovation

Trials integrate advanced imaging (PET/CT, 68Ga-FAPI) and biomarkers for patient stratification, alongside patient-centric designs tracking prognosis in neoadjuvant rectal cancer and immunotherapy regimens. Real-world evidence from multimorbidity studies supports broader applicability.

Clinical Trial Participation Guide

Leverage Trial Radar’s Participation assistant to simplify summaries, preview steps with What to Expect, and check eligibility. Use the Contacts & Locations tab for site details and direct study team outreach.

Explore Peking Union Medical College clinical trials

View 50 of 477 results.